ES2572703T3 - Derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-il)picolinamida como antagonistas del receptor de orexina - Google Patents

Derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-il)picolinamida como antagonistas del receptor de orexina Download PDF

Info

Publication number
ES2572703T3
ES2572703T3 ES12791862.1T ES12791862T ES2572703T3 ES 2572703 T3 ES2572703 T3 ES 2572703T3 ES 12791862 T ES12791862 T ES 12791862T ES 2572703 T3 ES2572703 T3 ES 2572703T3
Authority
ES
Spain
Prior art keywords
triazol
morpholin
benzyl
methanone
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12791862.1T
Other languages
English (en)
Spanish (es)
Inventor
Martin Bolli
Christoph Boss
Christine Brotschi
Bibia Heidmann
Thierry Sifferlen
Jodi T. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Application granted granted Critical
Publication of ES2572703T3 publication Critical patent/ES2572703T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES12791862.1T 2011-11-08 2012-11-07 Derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-il)picolinamida como antagonistas del receptor de orexina Active ES2572703T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2011054976 2011-11-08
WOPCT/IB2011/054976 2011-11-08
PCT/IB2012/056218 WO2013068935A1 (en) 2011-11-08 2012-11-07 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists

Publications (1)

Publication Number Publication Date
ES2572703T3 true ES2572703T3 (es) 2016-06-01

Family

ID=47258050

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12791862.1T Active ES2572703T3 (es) 2011-11-08 2012-11-07 Derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-il)picolinamida como antagonistas del receptor de orexina

Country Status (28)

Country Link
US (1) US9150566B2 (https=)
EP (1) EP2776430B1 (https=)
JP (1) JP5718535B2 (https=)
KR (1) KR101676930B1 (https=)
CN (1) CN103917538B (https=)
AR (1) AR088692A1 (https=)
AU (1) AU2012335194B2 (https=)
BR (1) BR112014010617B1 (https=)
CA (1) CA2846568C (https=)
CL (1) CL2014000659A1 (https=)
CY (1) CY1117638T1 (https=)
DK (1) DK2776430T3 (https=)
EA (1) EA024106B1 (https=)
ES (1) ES2572703T3 (https=)
HR (1) HRP20160678T1 (https=)
HU (1) HUE029239T2 (https=)
IL (1) IL232462A (https=)
IN (1) IN2014CN04127A (https=)
MX (1) MX343837B (https=)
MY (1) MY167791A (https=)
PH (1) PH12014500852A1 (https=)
PL (1) PL2776430T3 (https=)
SG (1) SG11201401665WA (https=)
SI (1) SI2776430T1 (https=)
TW (2) TWI565703B (https=)
UA (1) UA112317C2 (https=)
WO (1) WO2013068935A1 (https=)
ZA (1) ZA201404189B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
ES2672732T3 (es) 2012-02-07 2018-06-15 Eolas Therapeutics Inc. Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina
KR101689093B1 (ko) 2012-06-04 2016-12-22 액테리온 파마슈티칼 리미티드 벤즈이미다졸-프롤린 유도체
CA2902135A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
HK1225731B (en) 2013-12-03 2017-09-15 Idorsia Pharmaceuticals Ltd Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
HRP20181710T1 (hr) 2013-12-04 2018-12-28 Idorsia Pharmaceuticals Ltd Uporaba derivata benzimidazol-prolina
JP2017024990A (ja) * 2013-12-13 2017-02-02 大正製薬株式会社 オキサゾリジン及びオキサジナン誘導体
JP5907310B2 (ja) * 2013-12-13 2016-04-26 大正製薬株式会社 オキサジナン化合物の結晶形及びその製造方法
EP3143999A4 (en) 2014-05-16 2017-12-20 The University of Tokyo Depression treatment agent
JP6663909B2 (ja) 2014-08-13 2020-03-13 エオラス セラピューティクス, インコーポレイテッド オレキシンレセプターモジュレーターとしてのジフルオロピロリジン
WO2016095205A1 (en) * 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Heteroaryl orexin receptor antagonists
CN104557744B (zh) * 2014-12-23 2017-04-12 广东东阳光药业有限公司 一种三氮唑化合物的制备方法
WO2017088759A1 (en) 2015-11-23 2017-06-01 Sunshine Lake Pharma Co., Ltd. OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
MX2018009656A (es) 2016-02-12 2019-02-20 Astrazeneca Ab Piperidinas halo-sustituidas como moduladores de los receptores de orexinas.
HRP20211304T1 (hr) 2017-05-03 2021-11-12 Idorsia Pharmaceuticals Ltd Pripravljanje derivata 2-([1,2,3]triazol-2-il)-benzojeve kiseline
WO2020099511A1 (en) * 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
GB201901142D0 (en) * 2019-01-28 2019-03-20 Heptares Therapeutics Ltd OX1 Antagonists
EP4288432A1 (en) * 2021-02-02 2023-12-13 Idorsia Pharmaceuticals Ltd A crystalline form of (4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(r)-3-(3-[1,2,3]triazol-2-yl-benzyl)-morpholin-4-yl]-methanone
AR129309A1 (es) * 2022-05-13 2024-08-07 Idorsia Pharmaceuticals Ltd Derivados de hidrazina-n-carboxamida cíclica sustituida con tiazoloaril-metilo
CN115947697A (zh) * 2022-12-28 2023-04-11 苏州汉德创宏生化科技有限公司 一种3-氧代吗啉-4-羧酸叔丁酯的合成方法
JPWO2024214321A1 (https=) * 2023-04-10 2024-10-17
GB202311280D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists
GB202311281D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130432A (en) 1990-12-21 1992-07-14 Syntex (U.S.A.) Inc. Process for preparing cyclic amines and intermediate products thereof
WO1993000313A2 (en) 1991-06-27 1993-01-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
US20040192673A1 (en) * 2001-05-05 2004-09-30 Pascale Gaillard N-aroyl cyclic amine derivatives as orexin receptor antagonists
BR0210609A (pt) * 2001-06-28 2004-07-20 Smithkline Beecham Plc Derivados de amina cìclica n-aroila como antagonistas do receptor da orexina
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) * 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0130335D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
PT1751111E (pt) 2004-03-01 2015-04-01 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,4-tetrahidroisoquinolina substituída
US20090082394A1 (en) 2006-03-15 2009-03-26 Actelion Pharmaceuticals, Ltd. Tetrahydroisoquinoline Derivatives to Enhance Memory Function
CA2657623A1 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
GB0620818D0 (en) 2006-10-19 2006-11-29 Ucb Sa Therapeutic agents
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
WO2009040730A2 (en) 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
AU2009307916A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
EP2349269A4 (en) 2008-10-21 2012-04-25 Merck Sharp & Dohme 2,5-DISUBSTITUTED PIPERIDINOREXINE RECEPTOR ANTAGONISTS
AU2009307913A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
JP2012510494A (ja) 2008-12-02 2012-05-10 グラクソ グループ リミテッド N−{[(ir、4s、6r)−3−(2−ピリジニルカルボニル)−3−アザビシクロ[4.1.0]ヘプタ−4−イル]メチル}−2−ヘテロアリールアミン誘導体およびその使用
AR074426A1 (es) 2008-12-02 2011-01-19 Glaxo Group Ltd Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
ES2585806T3 (es) 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators

Also Published As

Publication number Publication date
MX343837B (es) 2016-11-24
JP5718535B2 (ja) 2015-05-13
CN103917538A (zh) 2014-07-09
TW201323421A (zh) 2013-06-16
PH12014500852A1 (en) 2016-03-02
CN103917538B (zh) 2016-08-24
CA2846568C (en) 2020-01-14
CY1117638T1 (el) 2017-04-26
EA201400553A1 (ru) 2014-10-30
JP2014532753A (ja) 2014-12-08
HRP20160678T1 (hr) 2016-07-15
SI2776430T1 (sl) 2016-06-30
CA2846568A1 (en) 2013-05-16
TWI565703B (zh) 2017-01-11
SG11201401665WA (en) 2014-09-26
AU2012335194A1 (en) 2014-07-03
HUE029239T2 (en) 2017-02-28
ZA201404189B (en) 2017-08-30
BR112014010617A2 (pt) 2017-04-25
EP2776430B1 (en) 2016-03-16
KR20140096338A (ko) 2014-08-05
BR112014010617B1 (pt) 2021-12-14
MY167791A (en) 2018-09-26
US9150566B2 (en) 2015-10-06
DK2776430T3 (en) 2016-05-09
TWI555747B (zh) 2016-11-01
IL232462A0 (en) 2014-06-30
AR088692A1 (es) 2014-06-25
PL2776430T3 (pl) 2016-09-30
BR112014010617A8 (pt) 2017-12-26
EA024106B1 (ru) 2016-08-31
AU2012335194B2 (en) 2017-05-25
CL2014000659A1 (es) 2014-08-18
WO2013068935A1 (en) 2013-05-16
NZ625896A (en) 2016-04-29
TW201632517A (zh) 2016-09-16
EP2776430A1 (en) 2014-09-17
KR101676930B1 (ko) 2016-11-16
US20150158855A1 (en) 2015-06-11
UA112317C2 (uk) 2016-08-25
IN2014CN04127A (https=) 2015-07-10
MX2014005635A (es) 2014-06-23
HK1199022A1 (zh) 2015-06-19
IL232462A (en) 2016-11-30

Similar Documents

Publication Publication Date Title
ES2572703T3 (es) Derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-il)picolinamida como antagonistas del receptor de orexina
TWI694076B (zh) 三唑并嘧啶化合物及其用途
EP2785713B1 (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
CN107787323B (zh) 用于抑制shp2活性的化合物和组合物
US20140357636A1 (en) Treatment of Skeletal-Related Disorders
WO2013054291A1 (en) Novel oxazine derivatives and their use in the treatment of disease
BR112014004310B1 (pt) Composto de pirimidina inibidor da enzima fosfodiesterase 10, composição farmacêutica, uso de um composto
KR20140015267A (ko) 진통, 정신질환, 인지장애 또는 알츠하이머병의 치료용 알파-7 니코틴 수용체 수식물질
JP2018016544A (ja) 新規ジアザビシクロ[2.2.2]オクタン誘導体
BR112018016446B1 (pt) Composto de piperidina halo-substituída, composição farmacêutica compreendendo dito composto e uso terapêutico dos mesmos
KR20150130413A (ko) 오렉신 수용체 길항제로서의 아제티딘 아미드 유도체
CN107207516B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
WO2024086179A1 (en) Pyrimidine sgc stimulators
EP2922823A1 (en) Pyrimidine pde10 inhibitors
JP2025502326A (ja) デオキシシチジンキナーゼ阻害剤
JP2025537514A (ja) 新規ジアシルグリセリドo-アシルトランスフェラーゼ2阻害薬としてのイミダゾピリジン誘導体及びイミダゾピリダジン誘導体の調製
HK1199022B (en) 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists
HK1237764A1 (en) Heteroaryl compounds for kinase inhibition